Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Cash & Equivalents (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Cash & Equivalents readings, the most recent being $214.0 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents changed 0.12% to $214.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $214.0 million, a 0.12% change, with the full-year FY2025 number at $214.0 million, changed 0.12% from a year prior.
  • Cash & Equivalents hit $214.0 million in Q4 2025 for Amicus Therapeutics, up from $190.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $385.9 million in Q3 2021 to a low of $148.8 million in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $212.5 million (2023), compared with a mean of $219.1 million.
  • Biggest five-year swings in Cash & Equivalents: surged 83.21% in 2021 and later crashed 39.31% in 2022.
  • Amicus Therapeutics' Cash & Equivalents stood at $245.2 million in 2021, then plummeted by 39.31% to $148.8 million in 2022, then skyrocketed by 65.98% to $247.0 million in 2023, then fell by 13.46% to $213.8 million in 2024, then grew by 0.12% to $214.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $214.0 million (Q4 2025), $190.6 million (Q3 2025), and $158.7 million (Q2 2025) per Business Quant data.